Opus Genetics, Inc. announced the dosing of the first pediatric patient in its Phase 1/2 trial for OPGx-LCA5, a gene therapy targeting Leber congenital amaurosis (LCA). Initial results from this ...
The ACTIVATE-Kids and ACTIVATE-KidsT Phase 3 studies mark Agios’ first pediatric clinical program for a rare hemolytic anemia, providing valuable insights that will help shape the company’s ...
About the CIDS Phase III The CIDS Phase III was a multicenter, multinational, randomized, controlled, open label study, conducted in pediatric patients with deep partial thickness (DPT ...
Cingulate (CING) released Phase 3 safety data for its lead asset CTx-1301 for the treatment of Attention Deficit Hyperactivity Disorder, ADHD.
An independent Data Safety Monitoring Board (DSMB) for the Phase 3 DRAGON trial recommends trial continuation without any modifications, maintaining the sample size at 104 subjects following a planned ...
MediWound (MDWD) announced the publication of its Phase III Children Innovative Debridement Study in Burns, the peer-reviewed Journal of the ...
Findings in Burns Journal confirm NexoBrid’s superiority over standard of care in pediatric patients with deep thermal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results